Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin

A legfontosabb adatok

Ki végzi
Avexima Diol LLC
Hol
Oroszország8 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
215 fő vett részt
Kezdés
2024. júl. 22.
Befejezés
2025. jan. 14.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Sodium enoxaparin
  • Dimolegin
  • Dimolegin placebo
  • Sodium enoxaparine placebo
A regiszteradat frissítve
2026. január 16.

Ki vehet részt

Életkor
18 év – 80 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 35 feltétel megnézéseKevesebb

Ki vehet részt

  • Men and women between the ages of 18 and 80
  • Patients scheduled for unilateral elective total hip or knee arthroplasty
  • The patient's voluntary informed consent
  • Negative pregnancy test result (for female patients with preserved reproductive potential)
  • Patients with reproductive potential should agree to use methods of contraception according to the protocol

Ki nem vehet részt

  • Surgery for an acute fracture (<4 weeks)
  • Collection of at least one volume unit of donated blood (≥ 450 ml) or blood transfusion during the previous 12 weeks
  • Surgery or injury during the last 90 days
  • Significant cardiovascular diseases currently or within 6 months prior to screening
  • The need for continuous use of antiplatelet drugs, which cannot be discontinued at least 4 days before the start of the investigational therapy
  • Systemic therapy with drugs with strong inducers and inhibitors of CYP3A4 and P-glycoprotein, which cannot be discontinued at least 7 days before the start of the investigational therapy
  • Participation in another clinical trial currently or within 90 days prior to screening
  • Inability to read or write; unwillingness to understand and follow the procedures of the study protocol; non-compliance with the study therapy or procedures
  • Increased risk of thrombosis
  • Active bleeding or increased risk of bleeding
  • Diseases of the digestive system that may disrupt the absorption of the study drug
  • Active liver or biliary tract diseases
  • Positive test result for HIV, syphilis, hepatitis B and C markers
  • The development of trophic disorders of the lower extremities that are not amenable to drug treatment
  • Any condition in which, in the opinion of the researcher, surgical intervention or the use of anticoagulants is contraindicated
  • Creatinine clearance, calculated according to the Cockcroft-Gault formula, less than 30 ml/min
  • Hemoglobin < 105 g/l in women or < 115 g/l in men
  • Abnormal results aboratory parameters of the coagulation system (platelets, APTT, prothrombin time, INR) beyond the limits of normal values
  • An increase in ALT or ACT ≥ 2 times from the upper limit of normal (ULN) or total bilirubin ≥ 1.5 times from ULN
  • Hypersensitivity or contraindications to the administration of Dimolegin®, enoxaparin sodium, unfractionated heparin or warfarin
  • Revision or extraction arthroplasty
  • Septic arthritis
  • The only lower limb
  • Current coagulopathy (patient's or his relative's) or congenital thrombophilia
  • Body mass index is less than 18.5 or more than 40 kg/m2
  • Body weight for women is less than 45 kg, for men less than 57 kg and above 130 kg for both
  • Systolic blood pressure > 180 mmHg and/or diastolic blood pressure >110 mmHg
  • The need for constant use of parenteral or oral anticoagulants
  • Pregnant or breast-feeding women
  • Affiliation to a research center, Sponsor, or contractual research organization

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This clinical study aims to evaluate the efficacy and safety of the anticoagulant Dimolegin® compared to low molecular weight heparin (Clexane®) for the prevention of venous thromboembolic events (VTE) in patients undergoing major joint (hip or knee) replacement surgery. The study will assess the incidence of VTE, VTE-related mortality, and all-cause mortality during different follow-up periods in both treatment groups. Additionally, the study will evaluate the frequency of bleeding events and the incidence, number, and characteristics of all adverse events associated with Dimolegin® and Clexane® therapy.

A vizsgálat 2 csoportja

  • 1 (Dimolegin® Group)A vizsgált kezelés

    Subgroup 1A (Hip Arthroplasty): Dimolegin® + placebo Clexane® for 35±2 days. Subgroup 1B (Knee Arthroplasty): Dimolegin® + placebo Clexane® for 14±1 days.

    Kezelés: Dimolegin és Sodium enoxaparine placebo

  • 2 (Clexane® Group)Már használt kezelés, összehasonlításként

    Subgroup 2A (Hip Arthroplasty): Clexane® + placebo Dimolegin® for 35±2 days. Subgroup 2B (Knee Arthroplasty): Clexane® + placebo Dimolegin® for 14±1 days.

    Kezelés: Sodium enoxaparin és Dimolegin placebo

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Randomized, Double-blind, Double-masked Prospective Multicenter Trial to Evaluate the Efficacy and Safety of the Oral Anticoagulant Dimolegin® Compared With Low Molecular Weight Heparin (Clexane®) as a Means of Preventing VTE in Patients Undergoing Elective Endoprosthetics of Large Joints
A regiszteradat frissítve
2026. január 16.